ScholarWorks@Hanyang University: Jun, Dae Won

Detailed Information

Jun, Dae Won (전대원)

서울 의과대학 (DEPARTMENT OF INTERNAL MEDICINE)

Research Area: 소화기내과, Gastroenterology

Tel 02-2290-8338
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Nonalcoholic fatty liver disease:19||Nonalcoholic fatty liver disease:11||Liver cirrhosis:10||Fatty liver:9||nonalcoholic fatty liver disease:9||hepatocellular carcinoma:9||Hepatocellular carcinoma:8||Korea:8||Metabolic syndrome:8||Obesity:7||Liver fibrosis:6||NAFLD:6||Treatment:6||Incidence:5||Nonalcoholic steatohepatitis:5||Hepatitis B:5||Necroptosis:5||Epidemiology:5||liver fibrosis:5||mortality:4||fatty liver:4||Prevalence:4||Nonalcoholic fatty liver:4||chronic hepatitis B:4||nonalcoholic steatohepatitis:4||Entecavir:4||Metaanalysis:4||HBV:4||fibrosis:4||Diagnosis:3||Mortality:3||hepatic fibrosis:3||irritable bowel syndrome:3||entecavir:3||Sarcopenia:3||Elastography:3||hepatitis B virus:3||hepatitis C virus:3||NA:3||magnetic resonance imaging:3||Liver Cirrhosis:3||magnetic resonance elastography:3||Predictive factors:3||Hepatitis C:3||Insulin resistance:3||Nonalcoholic Fatty Liver Disease:3||Carnitine:3||Biomarker:3||Colon cancer:3||chronic liver disease:3||liver cancer:3||MASLD:3||CHOP:2||Fibrosis:2||Fibrosis4 index:2||fat:2||Optic neuritis:2||tenofovir disoproxil fumarate:2||Hepatitis B virus:2||Low salt:2||Hepatitis C virus:2||type 2:2||Lymph node:2||Complications:2||Pancreas:2||MLKL:2||Parotid gland:2||Adenomatous polyps:2||Fructose:2||Acute kidney injury:2||Carcinosarcoma:2||hepatocellular:2||ER stress:2||GGT:2||Tenofovir:2||Carcinoma:2||Platelet count:2||Magnetic resonance elastography:2||Gastric cancer:2||Crohn&apos:2||Mesenchymal stem cell:2||liver:2||liver cirrhosis:2||Prediction:2||Chronic liver disease:2||Probability(P)value:2||Visceral fat area:2||Prognosis:2||Vitamin D:2||Cirrhosis:2||Metabolic dysfunctionassociated steatotic liver disease:2||alanine aminotransferase:2||Cystatin C:2||Metastasis:2||Biopsy:2||Genotype:2||Mitochondria:2||Ghrelin:2||Esophageal varices:2||Clinical trial:2||mitochondrial dysfunction:2||antiviral treatment:2||apoptosis:2||DA9701:2||Guideline:2||nonalcoholic fatty liver:2||DAA:2||Agestandardized incidence rate:2||carnitine:2||Awareness:2||NRF2:2||Leptin:2||chronic:2||HCC:2||Colon:2||cirrhosis:2||prevalence:2||Diabetes mellitus:2||Cell death:2||SREBP1:2||AMPK:2||Scaffold:2||Liver Cancer:2||deep neural networking:2||Adenocarcinoma:2||Sialadenitis:2||Hepatic encephalopathy:2||s disease:2||Alcoholic:2||screening:2||Hepatic fibrosis:2||Gastrointestinal diseases:1||Gastrointestinal endoscopy:1||Gastrointestinal stromal tumors:1||Gastrointestinal transit:1||Gastrostomy:1||Genes:1||Global burden of disease:1||Glucose intolerance:1||Green tea:1||Guidelines:1||H/L ratio:1||HBeAgpositive chronic hepatitis B:1||HBeAgpositive chronic infection:1||HCV:1||HbA1c:1||Hepatic Fibrosis:1||Helicobacter pylori:1||HepG2:1||Hepamet Fibrosis Score:1||Hepatic Fibrosis Burden:1||Hepatic and extrahepatic mortality:1||Hepatic fat content:1||Hepatiis C:1||Hepatitis A:1||Hepatitis B Virus:1||Highfat diet:1||Hong Kong:1||Hydrogen:1||HydroxymethylglutarylCoA reductase inhibitors:1||Hypoxia:1||Ileum:1||Ileus:1||Immunetolerant phase:1||Immunohistochemistry:1||Immunotherapy:1||Inactive Patients:1||Infection:1||Inflammatory Bowel Diseases:1||Insulinlike growth factor binding protein 1:1||International:1||Intestinal Gas:1||Intestinal permeability:1||Intraabdominal fat:1||Intrahepatic lipid:1||Intussusception:1||Irritable Bowel Syndrome:1||Irritable bowel syndrome:1||Japan:1||Knowledge adaptation:1||Kupffer cells:1||Lactobacillus:1||Lactulose Breath Test:1||Laparoscopic liver resection:1||Leaky gut syndrome:1||Lifestyle modification:1||Lightweight framework:1||Linkage to care:1||Lipid accumulation:1||Lipid partitioning:1||Lipoma:1||Lipotoxicity:1||Liver Disease:1||Liver X receptor:1||Liver X receptors:1||Liver cancer:1||Liver disease:1||Liver failure, acute:1||Liver neoplasms:1||Liver stiffness:1||Longterm followup:1||Low carbohydrate diet:1||Low fat diet:1||Low sodium:1||Lunch:1||MASH:1||MRE:1||MRI:1||MRIPDFF:1||MUC3:1||MUC5B:1||Mac2 binding protein glycosylation isomer:1||Mac2 binding protein glycosylation isomer (M2BPGi):1||Mac2binding protein:1||Magnetic Resonance Elastography:1||Magnetic resonance imaging:1||Malnutritionlivercirrhosishepatitis C virus (HCV)subjective global assessment (SGA)triceps skinfold thickness (TSF):1||Management:1||Metabolic abnormalities:1||Metabolic disease:1||Metabolic dysfunctionassociated fatty liver:1||Metabolic dysfunctionassociated steatohepatitis:1||MetabolicAssociated Fatty Liver:1||Methane:1||Microbiome:1||Minimal Hepatic Encephalopathy:1||Mitochondrial DNA copy number:1||Mixed lineage kinase domainlike protein:1||Moderate drinking:1||Multicenter:1||Muscle mass:1||N200:1||NAFLD/NASH:1||NASH:1||NITs:1||NLRP3:1||NRF2:1||Natural History:1||Natural history:1||Natural killer cell:1||Necrosis:1||Neoplasm:1||NiemannPick C1like 1:1||Nitric oxide:1||Nonalcoholic fatty liver disease (NAFID):1||Nonalcoholic fatty liver disease (NAFLD):1||Nonalcoholic steatohepatitis:1||Noninvasive diagnosis:1||Nonobese:1||Nonalcholic fatty liver disease:1||Nonalcoholic Fatty Liver:1||Nonalcoholic fatty liver:1||Noninvasive Test:1||Noninvasive test:1||Nrf2:1||Nutrition:1||Nutrition Therapy:1||Obeticholic acid:1||Osthol:1||Otsuka Long Evans Tokushima Fatty:1||Outcome:1||Overall survival:1||P300:1||PERK:1||POPs:1||Pancytopenia:1||Paracrine effect:1||Pediatric:1||Peginterferon Alfa2a:1||Pegylated interferon:1||Percutaneous endoscopic gastrostomy:1||Persistent organic pollutants:1||PhenoGraph:1||Phosphorylated extracellular signalregulated kinase:1||Pin1:1||Polymerase Chain Reaction:1||Polymorphism, Single nucleotide:1||Population groups:1||Population surveillance:1||Portal hypertension:1||Portosystemic shunt:1||Pretrained language model:1||Predictive value of tests:1||Probiotics:1||Programmed necrosis:1||Protease inhibitor:1||Proton pump inhibitor:1||Psoas muscle:1||Psychological test:1||Psychometric Test:1||Pulmonary diffusing capacity:1||P값:1||REALC:1||RIPK3:1||ROI:1||Randomized controlled trials:1||Randomized controlled trials as topic:1||Real world:1||Realworld:1||Realworld study:1||Receptor interacting protein kinase3:1||Receptorinteracting protein kinase:1||Recurrence:1||Referral and consultation:1||Renal function:1||Renal insufficiency:1||Response:1||Review:1||Risk Factor:1||Risk Factors:1||Risk factor:1||Rome II:1||Rome III:1||SAFE score:1||SIRT1:1||SIRT3:1||SVR:1||Safety:1||Sampling method:1||Sarcoma, myeloid:1||Score:1||Scoring system:1||Sericin:1||Serine:1||Significant fibrosis:1||Singlenucleotide polymorphism:1||Skeletal muscle index:1||Smad2/3:1||Small intestinal injury model:1||Social stigma:1||Sorafenib:1||South Korea:1||Standardized uptake value:1||Standards:1||Steatosis:1||Stem cell:1||Steroid:1||Sterol regulatory element binding protein:1||Sterol regulatory elementbinding protein1c:1||Stroop test:1||Subclinical atherosclerosis:1||Substage:1||Sugars:1||Sunlight exposure:1||Surgical resection:1||Surrogate marker:1||Surveillance:1||Sustained virologic response:1||Systematic:1||TDF:1||TGF:1||TGFbeta 1:1||TXNIP:1||Taiwan:1||Target therapy:1||Terminology:1||Therapeutic endoscopy:1||Thioctic acid:1||Tolerability:1||Transjugular intrahepatic portosystemic shunt:1||Treatment rate:1||Tumor lysis syndrome:1||Tumor necrosis factoralpha:1||Tyrosine kinase inhibitor:1||Ulcerative:1||Untreated patients:1||VEGF:1||Variant angina:1||Varices:1||Vascular endothelial growth factor inhibitor:1||Visceral Obesity:1||Visceral hypersensitivity:1||acetylcarnitine:1||adhesion:1||advanced fibrosis:1||advanced hepatic fibrosis:1||alcohol:1||alphafetoprotein:1||alternative test method development:1||angiogenesis:1||antibacterial agents:1||antigen:1||antiviral:1||antiviral agent:1||antiviral selection:1||area under the receiver operating characteristics curve:1||aryl hydrocarbon receptor:1||ascites:1||aspartate aminotransferase:1||atrisk population:1||atherosclerotic cardiovascular disease risk (ASCVD):1||biomarker:1||bone density:1||caffeine:1||carbohydrate:1||carnitineorotate:1||cause of death:1||cell death:1||chronic hepatitis C:1||chronic liver disease (CLD):1||clinical:1||clopidogrel:1||cluster:1||cognitive alteration:1||cohort:1||colon cancer:1||comorbidity:1||computed tomographic colonoscopy:1||constipation:1||controlled attenuation parameter:1||costeffectiveness:1||decompensated liver cirrhosis:1||deep immune profiling:1||delivery of health care:1||diabetes:1||diabetes mellitus:1||diagnosis rate:1||dioxins:1||direct–acting antivirals:1||directacting agent:1||directacting antiviral:1||directacting antivirals:1||drug screening:1||dyspepsia:1||educational program:1||elderly:1||encapsulation:1||extrahepatic malignancy:1||extrahepatic mortality:1||fibrosis4 index:1||food allergy:1||functional nearinfrared spectroscopy (fNIRS):1||gastroesophageal reflux disease:1||gastroscopy:1||ghrelin:1||granulocyte colony stimulating factor:1||guamerin:1||gut microbiota:1||haemodynamic response:1||health checkup cohort:1||hepatic encephalopathy:1||hepatic inflammation:1||hepatic steatosis:1||hepatic stellate cell:1||hepatitis B:1||individual patient data:1||inflammasome:1||inflammation:1||insulin resistance:1||interleukin6:1||intestinal permeability:1||lactic acidosis:1||lemon balm:1||leptin:1||leukocyte elastase inhibitor:1||linkage to care:1||lipogenesis:1||lipotoxicity:1||liver biopsy:1||liver disease:1||liver function tests:1||mac2 binding protein glycan isomer:1||macro‐:1||magnetic resonance spectroscopy:1||malignancy:1||mass cytometry:1||mast cell:1||measurement:1||melodic contour identification:1||metaanalysis:1||metabolic abnormality:1||metabolic dysfunctionassociated fatty liver:1||metabolic dysfunctionassociated fatty liver disease:1||metabolic dysfunctionassociated steatotic liver disease:1||metabolic risk:1||metabolic syndrome:1||metabolism:1||microbiota:1||minimal hepatic encephalopathy:1||minimally invasive surgery (MIS):1||mitochondria:1||mitochondria copy number:1||mixed lineage kinase domainlike (MLKL):1||molecular:1||music perception:1||necroptosis:1||next generation probiotics:1||nonalcoholic fatty liver disease fibrosis score:1||nonalcoholic fatty liver:1||nonalcoholic steatohepatitis:1||nonverbal auditory perception:1||normal:1||nuts and seeds:1||obesity:1||pancreatitis:1||pathology:1||per rectum ²⁰¹Tl scintigraphy:1||phenotype:1||physicians:1||population groups:1||populationbased:1||posttreatment:1||precision medicine:1||prediction model:1||probiotic:1||probiotics:1||prognosis:1||propensity score matching:1||propranolol:1||prospective studies:1||protease inhibitor:1||proton density fat fraction:1||psychometric hepatic encephalopathy score:1||public health:1||racial/ethnic disparity:1||random survival forests:1||rates:1||reactivation:1||relative muscle mass:1||risk factors:1||risk prediction model:1||robotic liver resection:1||sarcopenia:1||sarpogrelate:1||scaffold:1||selfreported constipation:1||sequential therapy:1||shear wave:1||size:1||skin prick test:1||small intestinal bacterial overgrowth:1||steatosis:1||steatosis model:1||stellate cell:1||stem cell:1||stomach cancer:1||substance P:1||tenofovir:1||tenofovir alafenamide:1||thioacetamide:1||ticagrelor:1||treatment:1||tumor necrosis factoralpha:1||ultrasoundguided attenuation parameter:1||unmet need:1||upper limit of normal:1||validation study:1||vasoactive intestinal peptide:1||vegetables:1||virologic response:1||vitamin:1||volume:1||대장:1||대장암:1||렙틴:1||면역조직화학 염색:1||미토콘드리아:1||비알코올 지방간 질환:1||비알코올성 지방간:1||생활습관 개선:1||선암종:1||선종성 용종:1||식도 정맥류:1||실시간 중합효소연쇄반응:1||암육종:1||염증성 장질환:1||예측인자:1||췌장:1||치료:1||카르니틴:1||11 betaHydroxysteroid dehydrogenase type 1:1||혈소판수:1||3Phosphoglycerate dehydrogenase (PHGDH):1||5HT:1||5HT2A receptor:1||ABCA1:1||ABCG5:1||ABCG8:1||AFP:1||AICAR:1||ALSL1023:1||ALT:1||AST:1||ATP:1||Acute gastric injury:1||Acute liver failure:1||Advanced Hepatic Fibrosis:1||Advanced fibrosis:1||Advanced stage:1||Afternoon colonoscopy:1||Age:1||Alanine aminotransferase:1||Alcohol:1||Alcoholic fatty liver:1||Alternative pathway:1||Aminotransferase:1||Anatomy:1||Animal Model:1||Antioxidants:1||Antiviral Therapy:1||Antiviral agent:1||Antiviral therapy:1||Apoptosis:1||Artificial intelligence:1||Aryl hydrocarbon receptor ligands:1||Asia:1||Asia pacific:1||Asialo alpha 1acid glycoprotein:1||Asian:1||Aspartate AminotransferasetoPlatelet Ratio Index:1||Aspartate aminotransferase:1||Atrisk population:1||Auranofin:1||Autophagy:1||Azathioprine:1||BTT105:1||Bariatric:1||Berberine:1||Bile acid:1||Bleeding:1||Body mass index:1||Bowel preparation:1||CD36:1||CHC:1||Capassisted colonoscopy:1||Carbohydrate:1||Carbohydrates:1||Cardimetabolic:1||Cardiometabolic risk factors:1||CaseControl Studies:1||Central obesity:1||Chemical and drug induced liver injury:1||Cholecystectomy:1||Cholesterol:1||Chronic:1||Chronic hepatitis:1||Chronic hepatitis B:1||Chronic hepatitis C:1||Chronic kidney disease:1||Clinical practice guideline:1||Coffee:1||Cognitive Function:1||Colitis:1||Colonic neoplasms:1||Colorectal distension:1||Common bile duct:1||Common bile duct stones:1||Comparative effectiveness:1||Coronary artery vasospasm:1||Corydalis:1||Crohn’s disease:1||Crude incidence rate:1||Cumulative Incidence:1||Cyclooxygenase 2:1||Cyclooxygenase2:1||DA6034:1||DA9601:1||DNA:1||Decompensated cirrhosis:1||Decompensation:1||Diabetes:1||Diabetes mellitus, type 2:1||Diabetic nephropathy:1||Dialysis:1||Diet:1||Dipeptidyl peptidase 4 inhibitor:1||Direct Comparison:1||Directacting antiviral:1||Disease progression:1||Diverticulitis:1||Drugtarget interactions:1||ETV:1||Effectiveness:1||Endoscopic submucosal dissection:1||Endoscopic treatment:1||Endoscopy:1||Eosphagitis:1||Esophageal and gastric varices:1||Ethnic:1||Ethnicity:1||Eventrelated potentials:1||Exercise:1||Ezetimibe:1||F18FDG:1||FIB4:1||FIB4 Index:1||FXR:1||Faecalibacterium prausnitzii:1||Farnesoid X receptor:1||Fatty Liver:1||Fatty acid uptake:1||Fatty pancreas:1||Fermented soymilk:1||FlowSOM:1||Foxa2:1||Fruit:1||Function:1||Functional cure:1||GIST (gastrointestinal stromal tumors):1||Gallbladder epithelial cell:1||Gallstones:1||Gastroesophageal reflux:1||

RSS_1.0 RSS_2.0 ATOM_1.0

222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE